ABBV Infographic: AbbVie’s Q1 2023 earnings and revenue decline

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023. Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments. At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in […]

April 27, 2023 1 min read

“
Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023. Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments. At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in […]
· April 27, 2023

Pharmaceutical company AbbVie, Inc. (NYSE: ABBV) reported a decrease in first-quarter 2023 adjusted earnings and revenues. The company also provided guidance for fiscal 2023.

AbbVie Q1 2023 earnings infographic

Total revenues decreased 9.7% year-over-year to $12.23 billion, reflecting weakness in the main operating segments.

At $2.46 per share, adjusted net income was lower than the $3.16 per share reported in the prior-year period. First-quarter unadjusted profit dropped to $239 million or $0.13 per share from $4.49 billion or $2.51 per share in the first quarter of 2022.

“This year is off to an excellent start, with first-quarter revenues and EPS ahead of our expectations, driven by strong commercial execution across all areas of our diversified portfolio,” said Richard A. Gonzalez, CEO of AbbVie.